Introduction {#Sec1}
============

Benign breast disease (BBD), in addition to certain hormonal, anthropometric, and lifestyle factors, is a well-established risk factor for breast cancer \[[@CR1], [@CR2]\]. However, BBD comprises a broad spectrum of histological entities \[[@CR3]\]. Both epidemiologic and experimental studies suggest that non-atypical and atypical proliferative changes represent successive steps preceding the development of in situ cancer and then invasive carcinoma of the breast \[[@CR4]\]. However, only a small fraction of women will eventually develop breast cancer after their diagnosis of BBD \[[@CR5]\]. Therefore, it is important to differentiate BBD patients with a high risk of subsequent development of breast cancer from those with a low risk. Our understanding regarding this issue, however, is rather limited, although previous studies have suggested that factors such as type of histological subtype (e.g., atypical hyperplasia), menopausal status, and family history of breast cancer, might modify breast cancer risk among women with BBD \[[@CR6]\].

Computerized image analysis and morphometry can quantify a number of nuclear morphometric features such as nuclear size, nuclear shape, and chromatin texture \[[@CR7]\]. The evaluation of these features may facilitate the diagnosis and management of breast cancer patients \[[@CR8]--[@CR10]\]. Indeed, certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients \[[@CR11]--[@CR15]\]. Furthermore, a study by Mommers et al. \[[@CR16]\] observed that normal breast tissue or usual ductal hyperplasia harbored nuclear morphometric changes that might be used to predict subsequent development of breast cancer. In the study reported here, we conducted a nested case-control study to evaluate whether nuclear morphometric features as evaluated in tissue sections of BBD may be related to the risk of subsequent breast cancer among patients with BBD.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The present investigation was undertaken using histological sections from a previous case-control study nested within the cohort of 4,888 women in the Canadian National Breast Screening Study (NBSS) who were diagnosed histopathologically with BBD during the active follow-up phase of the NBSS \[[@CR17]\]. The NBSS is a multi-center randomized, controlled trial of screening for breast cancer among 89,835 women aged 40--59 years at recruitment. The design of the NBSS and population characteristics have been described in detail elsewhere \[[@CR18], [@CR19]\]. Recruitment took place between 1980 and 1985, and study subjects were followed actively until 1988. Eligibility for the study was restricted to women with no history of breast cancer (in situ or invasive). The NBSS was approved by the appropriate Institutional Review Boards, and the study described here involved the analysis of material and data from that study in accordance with the approved study design. Informed consent was obtained from all study participants.

Diagnosis of BBD {#Sec4}
----------------

In the NBSS, women who had clinical or radiologic evidence of breast lesion underwent either a needle aspiration or a biopsy. Diagnosis of BBD was performed by a reference pathologist. Our study was restricted to women who had no evidence of either in situ or invasive breast cancer on their initial surgical biopsy. Women with a history of BBD were not excluded from the analyses. During the follow-up period, we identified 4,888 women with a histopathologic diagnosis of BBD, who were followed up for the subsequent development of breast cancer.

Selection of cases and controls {#Sec5}
-------------------------------

Incident cases of breast cancer were ascertained by record linkage with the provincial cancer registries, and death clearance was performed by linkage to the Canadian National Mortality Database \[[@CR18], [@CR19]\]. The dates of the linkages varied by province, ranging from late 1988 to early 1991. A total of 16 subjects with ductal carcinoma in situ and 76 subjects with invasive carcinoma were ascertained among the cohort of women with BBD. Potential control subjects were women with BBD who had not developed breast cancer (but were alive at) by the date of diagnosis of the corresponding case subject. Five controls were selected randomly (with replacement) for each case from those non-cases available within strata defined by screening center, NBSS study arm, year of birth (if possible to the nearest year, and mostly within 2 years), and age at diagnosis of BBD. For the study reported here, 61 case subjects and 71 control subjects (including 53 matched case-control sets) were included.

Questionnaire {#Sec6}
-------------

Upon enrollment in the NBSS, all participants completed a questionnaire that sought information on demographic characteristics and risk factors for breast cancer, including menstrual and reproductive histories and family history of breast cancer.

Morphometry {#Sec7}
-----------

Morphometric measurements were performed on H&E stained slides, using the QPRODIT interactive video-overlay system (Leica, Cambridge, UK). About 50 nuclei were selected in the most representative areas of the slide (selected by a breast pathologist), and their contours were traced manually using a 100× objective (final magnification about 3,000×) \[[@CR20]\]. Mean and standard deviation of nuclear area, perimeter, diameter, shortest axis, longest axis, and axis ratio were calculated, as well as different shape factors. The shape factors were calculated by the following formulas: Form_AR = (1/4) \* pi \* longest axis \* shortest axis; Form_PE = 4 \* pi \* area/(perimeter squared); Form_NCI = perimeter/sqrt (area); Contour ratio = perimeter squared/4 \* pi \* area; and Roundness = perimeter/(2\*sqrt (pi \* area)). All morphometric assessments were performed by one observer without knowledge of patient outcome.

Statistical analysis {#Sec8}
--------------------

Morphometric measurements were first compared between cases and controls using Student's *t*-test. Subsequently, the measurements were categorized by quartiles and then odds ratios (OR) and 95% confidence limits (CLs) were calculated for the risk of breast cancer for those in the highest quartile level compared to that for those in the lowest 3 quartile levels using conditional logistic regression. In multivariate analyses, we controlled for age at menarche (\<13, 13, 14+), age at first live birth (nulliparous, \<23, 23--26, 27+), menopausal status (pre-, peri-, post-), oral contraceptive use (ever versus never), postmenopausal estrogen use (ever vs. never), body mass index (\<25, 25+), family history of breast cancer, and the presence of hyperplasia in the benign tissue. All statistical analyses were performed in SAS 9.1 (SAS Institute, Cary, NC). *P*-values were two-sided.

Results {#Sec9}
=======

Table [1](#Tab1){ref-type="table"} summarizes the distribution of selected characteristics among the cases and controls. Overall, few differences between the cases and controls were observed for age at menarche, age at first live birth, menopausal status, oral contraceptive use, postmenopausal estrogen use, body mass index, family history of breast cancer, and the presence of hyperplasia in benign tissue. Table 1.Distribution of selected characteristics among breast cancer cases and non-cases*N* (%)*P*-valueCasesControlsAge at menarche\<1330 (49)26 (37)0.291313 (21)22 (31)14+18 (30)23 (32)Age at first live birthNulliparous11 (18)9 (13)0.84\<2322 (36)29 (41)23--2619 (31)23 (32)27+9 (15)10 (14)Menopausal statusPre-30 (49)31 (44)0.71Peri-9 (15)14 (20)Post-22 (36)26 (36)Ever used oral contraceptivesYes35 (57)42 (60)0.76No26 (43)28 (40)Missing01Ever used postmenopausal estrogensYes15 (25)15 (22)0.70No46 (75)54 (78)Missing02Body mass index (kg/m^2^)\<2532 (53)41 (58)0.4225-- \< 3027 (44)25 (35)30+2 (3)5 (7)Family history of breast cancerYes23 (38)28 (39)0.84No38 (62)43 (61)Hyperplasia in benign tissueAbsent34 (59)47 (68)0.27Present24 (41)22 (32)Missing32

There was little difference between the cases and controls with respect to nuclear morphometric features including mean area, standard deviation (SD) of area, perimeter, diameter, shortest axis, and longest axis, as well as such shape factors as Form_PE, Form_NCI, contour, and roundness (Table [2](#Tab2){ref-type="table"}). In contrast, the shape factor Form_AR was greater among cases than among controls. Furthermore, subjects with hyperplasia had greater measures of some nuclear size features including mean area, SD of area, perimeter, diameter, and longest axis, and the shape factor Form_AR than did subjects without hyperplasia (data not shown). Table 2.Comparison of nuclear morphometric features in benign breast tissue between breast cancer cases and non-casesMorphometric measurementsMean (standard deviation)*P*-valueCases (*n* = 61)Controls (*n* = 71)Mean nuclear area (μm^2^)26.8 (7.5)25.3 (7.2)0.25SD of nuclear area (μm^2^)5.2 (1.8)5.0 (1.6)0.43Nuclear perimeter (μm)19.7 (2.7)19.3 (2.7)0.37Nuclear diameter (μm)5.8 (0.8)5.6 (0.8)0.23Shortest nuclear axis (μm)4.8 (0.7)4.6 (0.7)0.16Longest nuclear axis (μm)7.1 (1.0)7.0 (1.0)0.53Axis ratio1.5 (0.1)1.6 (0.2)0.15Form_AR0.984 (0.005)0.981 (0.007)0.0089Form_PE0.844 (0.037)0.831 (0.045)0.083Form_NCI3.874 (0.095)3.909 (0.122)0.071Contour1.198 (0.061)1.221 (0.080)0.068Roundness1.093 (0.027)1.103 (0.034)0.071

Quartile analyses revealed that subsequent breast cancer risk was increased in association with the shape factor Form_AR, but not with the other nuclear morphometric measurements (Table [3](#Tab3){ref-type="table"}). Compared to BBD subjects with Form_AR equal to or less than 0.986, subjects with Form_AR greater than 0.986 had a more than three-fold increased risk of developing breast cancer subsequently (OR = 3.07, 95%CL = 1.61, 5.84). When the analyses were repeated using unconditional logistic regression, which enabled all the available cases and controls to be included, the results did not change substantially. Table 3.Risk of Subsequent development of breast cancer in association with nuclear morphometric features^a^Morphometric measurementsCut-off valueOR (95% CL)Model 1^b^Model 2^c^Mean nuclear area (μm^2^)31.21.28 (0.73, 2.25)0.94 (0.50, 1.78)SD of nuclear area (μm^2^)6.11.33 (0.76, 2.31)1.11 (0.59, 2.07)Nuclear perimeter (μm)21.41.14 (0.70, 1.93)0.85 (0.47, 1.55)Nuclear diameter (μm)6.31.29 (0.73, 2.27)0.95 (0.50, 1.79)Shortest nuclear axis (μm)5.21.62 (0.92, 2.86)1.18 (0.62, 2.26)Longest nuclear axis (μm)8.01.34 (0.75, 2.39)0.95 (0.50, 1.81)Axis ratio1.60.59 (0.30, 1.17)0.71 (0.33, 1.54)Form_AR0.9862.45 (1.42, 4.22)3.07 (1.61, 5.84)Form_PE0.8671.22 (0.71, 2.08)1.57 (0.83, 2.97)Form_NCI3.9351.07 (0.58, 1.98)1.18 (0.61, 2.27)Contour1.2361.13 (0.61, 2.10)1.22 (0.63, 2.35)Roundness1.1101.07 (0.58, 1.98)1.18 (0.61, 2.27)^a^ Analyses were conducted among 53 matched case-control sets by comparing the highest quartile versus the lowest 3 quartiles in conditional logistic regression models^b^ Adjusted for matching variables^c^ Adjusted for matching variables, age at menarche (\<13, 13, 14+), age at first live birth (nulliparous, \<23, 23--26, 27+), menopausal status (pre-, peri-, post-), oral contraceptive use (ever vs. never), postmenopausal estrogen use (ever versus never), body mass index (\<25, 25+), family history of breast cancer, and the presence of hyperplasia in the benign tissue

Discussion {#Sec10}
==========

We found that breast cancer risk in women with BBD was positively associated with the shape factor Form_AR, a measurement that takes the shortest nuclear axis and the longest nuclear axis into consideration simultaneously. In contrast, there was no alteration in risk in association with nuclear area, SD of nuclear area, nuclear perimeter, nuclear diameter, shortest nuclear axis, longest nuclear axis, and other shape factors. Although subjects with hyperplasia had greater measures of Form_AR than did subjects without hyperplasia, we adjusted for hyperplasia, suggesting that the association with Form_AR is independent of that due to the presence of hyperplasia.

Shape is one of the factors that pathologists use in assessing nuclear atypicality. Shape factors have been shown to have prognostic value in breast cancer \[[@CR21]--[@CR23]\], renal cell cancer \[[@CR24]\], colorectal cancer \[[@CR25]\], squamous cell carcinoma of the larynx \[[@CR26]\], melanoma \[[@CR27]\], and rhabdomyosarcoma \[[@CR28]\]. Apparently, alterations in nuclear shape can already be present at the earliest stages of carcinogenesis. This has in the breast also been shown for nuclear chromatin patterns \[[@CR29]\].

To date, only one study has been published that assessed morphometric features in association with subsequent development of breast cancer among women with BBD \[[@CR16]\]. That study found positive associations for mean nuclear area, nuclear diameter, nuclear perimeter, and the longest nuclear axis, but no associations for SD of the nuclear area and the shortest nuclear axis; shape factors were not evaluated. However, potential confounding factors were not controlled for. In contrast to these findings, nuclear size features were not associated with risk in the present study, which may perhaps be explained by differences in tissue processing procedures.

Our case-control study was nested in a cohort of patients with histopathologically confirmed BBD and our findings are likely to be internally valid. Biased measurement of the study exposures was not likely a source of error, given that the morphometric features were assessed without knowledge of the patient outcome status. Our study power, however, was limited by the relatively small sample size, due to which we were not able to evaluate modifying effects by well-documented risk factors of breast cancer. Moreover, residual confounding might still exist, although to minimize confounding we controlled for menstrual and reproductive history, exogenous estrogen use, body mass index, and family history of breast cancer in multivariate analyses.

In conclusion, our study results suggest that the shape factor that takes both shortest nuclear axis and longest nuclear axis into consideration might be of value to predict subsequent development of breast cancer among patients with BBD. Given the limitations of our study, larger studies are warranted to confirm our study results.

We are indebted to the study participants for their dedication and commitment.
